Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint Medicines announced new data reinforcing the sustained clinical efficacy and ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Fintel reports that on June 17, 2025, Wells Fargo downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 0.45% Downside ...

Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on ...

A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a ...

STAT+ subscribers can sign up here to get it delivered to their inbox. Cogent Biosciences and Blueprint Medicines are direct competitors who hate each other.

Blueprint Medicines Corp (NASDAQ: BPMC) stock reached a significant milestone, hitting an all-time high of 128.34 USD. According to InvestingPro analysis, the stock appears overvalued at current ...